
Compounded Semaglutide vs Ozempic: Why They Are Not the Same
Compounded semaglutide isn't Ozempic. What changed after the shortage ended, FDA's 2026 warnings, the dosing-error risk, and whether it still saves money.
No, compounded semaglutide is not the same as Ozempic. Ozempic is an FDA-approved product made by Novo Nordisk in a prefilled pen with a fixed dose. Compounded semaglutide is mixed by a pharmacy, usually sold in a vial you draw up with a syringe, and it hasn't been reviewed by FDA for safety, effectiveness or quality. The active ingredient may be similar on paper, but the product in your hand can be very different.
Compounded semaglutide made sense for many people during the 2022–2025 shortage. In October 2026 the situation is different: the shortage is over, legal compounding is much narrower, and brand-name prices have dropped. Here's what changed and how to judge any offer you see.
Ozempic vs Compounded Semaglutide at a Glance
How the two compare
FDA approval
Yes, reviewed for safety, effectiveness and manufacturing quality
No; compounded drugs aren't FDA-approved
Who makes it
Novo Nordisk
A compounding pharmacy or outsourcing facility, often unnamed on the website
Form
Prefilled pen, dose set in milligrams
Usually a multi-dose vial and syringe, sometimes dosed in "units"
Active ingredient
Semaglutide base
Should be semaglutide base; some products have used salt forms FDA says aren't equivalent
Added ingredients
None beyond the approved formula
Often B12, glycine or L-carnitine
Evidence
Large clinical trials, including heart and kidney outcomes
No trials on the specific product
Cash price (Oct 2026)
$349/month up to 1 mg, $499 for 2 mg; tablets from $149
Varies; the gap with brand pricing has narrowed
Is Compounded Semaglutide Still Legal in 2026?
Only in narrow cases. Compounding pharmacies were allowed to make copies of semaglutide while it was on FDA's shortage list. FDA declared the shortage over in February 2025, and the grace periods for compounding pharmacies and outsourcing facilities ended that spring.
Since then, a pharmacy can generally compound semaglutide only when a prescriber documents a specific clinical need that the approved product can't meet, such as an allergy to an ingredient. That's why many online offers now advertise "personalized doses" or semaglutide "with B12": the add-ins are partly there so the product isn't technically a straight copy. Adding a vitamin doesn't make a product approved, tested or safer.
FDA has been sending warning letters to telehealth companies selling these products, including 25 letters in June 2026 alone. The claims it flagged are worth recognizing, because you'll see them in ads.
- 1"FDA-approved semaglutide" or "made with FDA-approved ingredients": compounded drugs are not FDA-approved.
- 2"Same results as Ozempic or Wegovy at a fraction of the cost": FDA has called this misleading, because the compounded product hasn't been tested.
- 3"Our pharmacies are FDA-approved": FDA doesn't approve or license pharmacies.
The Biggest Real Risk: Getting the Dose Wrong
If you remember one thing from this article, make it this. The most common serious problem FDA has documented with compounded semaglutide isn't contamination; it's overdose from measuring mistakes.
Ozempic pens are dosed in milligrams and you can only select set doses. Compounded vials come in different concentrations, and some are labeled in "units" meant for an insulin syringe. FDA has received reports of people drawing up 5 to 20 times their intended dose, and of prescribers miscalculating the conversion from milligrams to units, leading to doses 5 to 10 times too high. The results included severe vomiting, dehydration, fainting, pancreatitis and gallstones, and some people were hospitalized.
If you're using a vial, make sure you know three numbers before your first dose: your dose in milligrams, the vial's concentration in mg/mL, and exactly how many units or milliliters that equals on your syringe. Ask the pharmacist to show you, not just tell you. If you think you took too much, see our Ozempic overdose page or call Poison Control at 1-800-222-1222.
Salt Forms, "Research" Vials, and Counterfeits
Not every product sold as semaglutide is even the same molecule. FDA has said that semaglutide sodium and semaglutide acetate are different active ingredients from the semaglutide base in approved drugs, and they shouldn't be used to compound. Some sellers have used them anyway, and you can't tell from the vial.
Then there are products that aren't compounded at all: vials labeled "for research use only," powders sold through social media, and counterfeit Ozempic pens. FDA has found counterfeit Ozempic pens in the legitimate U.S. supply chain, too. These products have no prescriber, no licensed pharmacist and no quality controls, and they're the riskiest option on the market. Many of these sellers market semaglutide as just another "peptide." Our guide Is Ozempic a peptide? explains why sharing that label doesn't make them comparable.
Is Compounded Semaglutide Cheaper Now?
This is where the math has changed most. During the shortage, compounded semaglutide often cost a fraction of the $1,000-plus list price for Ozempic. In 2026, Novo Nordisk sells Ozempic directly at $349 a month for doses up to 1 mg, Ozempic tablets start at $149, and weight-loss options like the Wegovy pill and Foundayo also start at $149 for the lowest dose.
For many people, the savings from compounding have shrunk to a few dozen dollars a month, sometimes less, once you count the full price at a maintenance dose. That's a thin margin to trade for an untested product. Before choosing, compare the real monthly cost at the dose you'll actually be on. Our Ozempic cost guide and alternatives guide lay out current prices.
If You're Already Using Compounded Semaglutide
You don't need to panic, but you should check what you have. Many people use products from legitimate, state-licensed pharmacies without problems. The goal is to confirm yours is one of them.
- 1Find out the name of the pharmacy that actually made the product, not just the telehealth brand. It should be on the label.
- 2Check that pharmacy's license with your state board of pharmacy. An outsourcing facility (503B) should appear on FDA's registered list.
- 3Ask whether the active ingredient is semaglutide base, not a sodium or acetate salt.
- 4Confirm the concentration in mg/mL and your dose in both milligrams and syringe units.
- 5Check that it arrived cold, if the label says to refrigerate. FDA has received complaints about warm shipments.
- 6If you want to switch to Ozempic or another approved drug, ask your prescriber how to convert your dose. Don't assume the numbers match.
Bottom Line
Compounded semaglutide and Ozempic share an active ingredient on paper, but they aren't the same product, and only one has been tested and approved. The shortage that justified compounding is over, the legal window is narrow, and brand prices have come down enough that the savings are often small. If you do use a compounded product, know exactly who made it and exactly how much you're injecting.
FAQ
No. It may contain the same active ingredient, but it's made by a compounding pharmacy, hasn't been FDA-reviewed, and often comes in a vial with a different concentration and added ingredients.
No. A generic is FDA-approved and proven equivalent to the brand. There's no FDA-approved generic semaglutide in the U.S. as of October 2026.
Only in limited cases, generally when a prescriber documents a specific clinical need that the approved product can't meet. FDA has been sending warning letters to sellers that market compounded versions as equivalent to Ozempic or Wegovy.
There's no good evidence that adding B12 makes semaglutide work better. Add-ins are often used so a product isn't considered a direct copy of the approved drug.
Dosing errors. FDA has documented people taking 5 to 20 times their intended dose because of confusion between milligrams, milliliters and syringe units, leading to hospitalizations.
Yes, with your prescriber's help. Doses don't always match one-to-one, so don't assume your current number converts directly to an Ozempic pen setting.
Sources
- 1FDA's concerns with unapproved GLP-1 drugs used for weight loss, U.S. Food and Drug Administration
- 2FDA warning letter to Altru Telehealth on compounded semaglutide claims, FDA, June 2026
- 3FDA takes aim at misleading online claims for compounded GLP-1 drugs, McDermott, June 2026
- 4FDA warns of adverse events from overdosing compounded semaglutide, Healio
- 5Ozempic savings offer and self-pay pricing, NovoCare
- 6Ozempic (semaglutide) prescribing information, Novo Nordisk

Dr. Sheri Tomas
Author
Comments (0)
Be the first to comment on this article.




